Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid, which is drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals. Lymph nodes are an essential part of the lymphatic system. Lymphedema is largely caused due to the consequence of several cancer treatments. These include prostate, head and neck, and pelvic cancers such as those in bladder, testicles, ovaries, uterus, or cervix, along with lymphoma and melanoma. The swelling may occur on the part of the body that is treated. For instance, treating tumors in the belly or pelvis via radiation or surgery may cause swelling in the groin, genitals, belly, and one or both legs. Swelling in the face, eyes, or mouth can be caused by treatment for head & neck cancer.
Lymphatic filariasis (LF) continues to be a significant public health challenge in India. This vector-borne parasitic disease is extremely painful and disfigures the body parts causing severe disability, resulting in a condition called or elephantiasis. With over 40% of global LF cases found in India, it is a major threat to the country.
Approximately 640 million people in India are at risk of contracting the disease. LF has been reported in 336 districts across 20 States/Union Territories in India. 90% of the LF burden in India rests upon eight tropical states, including Uttar Pradesh, Bihar, Jharkhand, West Bengal, Chhattisgarh, Maharashtra, Odisha, and Madhya Pradesh.
According to National Disease Modelling Consortium stats, a total of 525,440 lymphedema cases were reported in India in 2021. Most lymphedema cases were reported from Bihar, Uttar Pradesh, Odisha, and Telangana. Furthermore, as per the news published in The Times of India, in February 2023, four cases of lymphedema were detected in Ahmedabad. In addition, 16 cases of lymphedema were detected in Tumakuru district in Karnataka from January 2022 to April 2022. Of these, the infection was majorly found in migrant workers from Bihar, Odisha, Uttar Pradesh, and Vijayapura district of Karnataka.
Thus, the rising number of lymphatic filariasis eventually drives the lymphedema treatment market in India.
Cancer and its treatments, such as surgery and radiation therapy, may sometimes change, block, or interrupt the flow of lymph fluid across the lymphatic system. When edema develops from a build-up of lymphatic fluid, it is referred to as lymphedema. This abnormal collection of fluid causes swelling in specific areas of the body, most often in the arms or legs. If untreated, lymphedema may lead to decreased function and mobility in the affected limb, skin issues, pain and discomfort, and other complications. An accumulation of protein-rich lymph fluid may lead to increased swelling, hardening of the tissue, and infection.
Lymphedema is most often associated as a side effect of breast cancer. Breast cancer patients are majorly at risk of developing lymphedema because axillary lymph nodes in the armpit near the breast may be removed or damaged by breast cancer surgery, radiation therapy, or a combination of cancer treatments. Lymphedema may also result from treatment for prostate cancer, gynecological cancers, lymphoma, melanoma, or other cancers. The more lymph nodes are removed or damaged, the higher the risk of developing lymphedema.
As per Globocan 2020 stats, nearly 178,361 cases were found in India, and approximately 90,408 died from the disease. The most general complication of breast cancer treatment is lymphedema. Moreover, as per the consensus coordinated by the Division of NCD Indian Council of Medical Research 2022, prostate cancer appears to be a growing problem in males in India. The incidence of prostate cancer has been steadily increasing in recent years. As per the NCDIR database, prostate cancer features among the top 10 cancers in urban cancer registries of Bengaluru, Delhi, Bhopal, and Mumbai. There were 37,416 reported prostate cancer cases in 2016 in India, which increased to 41,532 in 2020. As per the same source, prostate cancer incidence is expected to increase to over 47,000 cases by 2025.
Thus, the rising incidence of cancer cases, especially breast and prostate cancer, prompting radiation therapy and surgeries for treatment propel the lymphedema treatment market in India.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 926.65 Million |
| Market Size by 2030 | US$ 1,511.06 Million |
| Global CAGR (2022 - 2030) | 12.29% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Condition Type
|
| Regions and Countries Covered | India
|
| Market leaders and key company profiles |
The List of Companies - India Lymphedema Treatment Market
Companies operating in the market are Essity AB, Lympha Press USA Ltd, AIROS Medical Inc, 3M Co, Bio Compression Systems Inc, Lohmann & Rauscher GmbH & Co KG, Huntleigh Healthcare Ltd, Dynamic Techno Medicals Pvt Ltd, Medi GmbH & Co KG, Datt Mediproducts Pvt Ltd, Smith & Nephew Plc, SIGVARIS Management AG, and Tactile Systems Technology Inc.
The “India Lymphedema Treatment Market” is segmented based on condition type, treatment type, and end user. Based on treatment type, the global lymphedema treatment market is segmented into compression devices and bandaging, drug therapy, physiological procedure, debulking procedure, and others. The physiological procedures segment is further segmented into lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT). The debulking procedures segment is sub-segmented into liposuction, surgical debulking, and others. The compression devices and bandaging segment held the largest share of the market in 2022. The physiological procedure segment is expected to register the highest CAGR in the market during 2022–2030. This is mainly due to the appropriate treatment procedures performed on lymphedema patients through LVA and VLNT. These two procedures are appropriate treatment options for patients suffering from lymphedema.
Prevalence of lymphatic filariasis, adverse effects of cancer treatment, and growing awareness of lymphedema are driving the market growth. However, the high cost of lymphedema treatment is hampering the market growth.
Based on condition type, the global lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment held the largest share of the market in 2022. The primary lymphedema segment is anticipated to register a higher CAGR during 2022–2030. Secondary lymphedema's significant share is usually attributed to cancer-related treatment, which is a prominent cause of secondary lymphedema.
Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid, which is drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals. Lymph nodes are an essential part of the lymphatic system. Lymphedema is largely caused due to the consequence of several cancer treatments. These include prostate, head and neck, and pelvic cancers such as those in bladder, testicles, ovaries, uterus, or cervix, along with lymphoma and melanoma. The swelling may occur on the part of the body that is treated. For instance, treating tumors in the belly or pelvis via radiation or surgery may cause swelling in the groin, genitals, belly, and one or both legs. Swelling in the face, eyes, or mouth can be caused by treatment for head & neck cancer.